36 patents
Utility
Roflumilast Formulations with an Improved Pharmacokinetic Profile
4 Jan 24
An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast.
David Osborne
Filed: 22 Aug 23
Utility
Compositions and Methods for Deep Dermal Drug Delivery
28 Dec 23
Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same.
David W. OSBORNE, Babak N. TOFIG
Filed: 16 Nov 21
Utility
Inhibition of Crystal Growth of Roflumilast
28 Dec 23
Roflumilast crystals have been shown to increase in size during storage.
David W. OSBORNE
Filed: 12 Sep 23
Utility
Topical roflumilast formulation having improved delivery and plasma half-life
21 Nov 23
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. Osborne
Filed: 1 Mar 23
Utility
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life
16 Nov 23
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. OSBORNE
Filed: 17 Jul 23
Utility
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
2 Nov 23
Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition.
David W. OSBORNE
Filed: 30 Jun 23
Utility
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
2 Nov 23
Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition.
David W. OSBORNE
Filed: 30 Jun 23
Utility
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
26 Oct 23
Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition.
David W. OSBORNE
Filed: 30 Jun 23
Utility
LAURETH-4 Containing Topical Formulations
26 Oct 23
The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin.
David W. OSBORNE
Filed: 29 Jun 23
Utility
Inhibition of crystal growth of roflumilast
24 Oct 23
Roflumilast crystals have been shown to increase in size during storage.
David W. Osborne
Filed: 23 Nov 20
Utility
Topical Roflumilast Formulation Having Antifungal Properties
12 Oct 23
The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast.
David Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE
Filed: 15 Jun 23
Utility
Self-preserving Topical Pharmaceutical Compositions Comprising Diethylene Glycol Monoethyl Ether
5 Oct 23
Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH.
David W. OSBORNE, Babak N. TOFIG
Filed: 15 Aug 22
Utility
Self-preserving Topical Pharmaceutical Compositions Comprising Diethylene Glycol Monoethyl Ether
5 Oct 23
Topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH.
David W. OSBORNE, Babak N. TOFIG
Filed: 17 May 23
Utility
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life
5 Oct 23
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. OSBORNE, Bhaskar CHAUDHURI, Archie W. THURSTON, JR.
Filed: 1 Mar 23
Utility
Self-preserving Topical Pharmaceutical Compositions Comprising Diethylene Glycol Monoethyl Ether
14 Sep 23
Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH.
David W. OSBORNE, Babak N. TOFIG
Filed: 31 Oct 22
Utility
Laureth-4 containing topical formulations
22 Aug 23
The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin.
David W. Osborne
Filed: 27 Jul 21
Utility
Topical roflumilast formulation having antifungal properties
25 Jul 23
The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast.
David Reuben Berk, Patrick Eugene Burnett, Saori Kato, David W. Osborne
Filed: 3 Dec 21
Utility
Compositions and Methods for Deep Dermal Drug Delivery
20 Jul 23
Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same.
David W. OSBORNE, Babak N. TOFIG
Filed: 22 Mar 23
Utility
Topical Roflumilast Aerosol Foams
29 Jun 23
The present invention is directed to an aerosol foam composition comprising roflumilast, an emulsifier blend containing cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphate and a hydrocarbon propellant.
David W. OSBORNE, SR.
Filed: 19 Aug 22
Utility
Pharmaceutical Compositions of Spironolactone for Deep Dermal Drug Delivery
11 May 23
Pharmaceutical compositions for the topical administration of spironolactone to the pilosebaceous unit and methods for administering the same.
David W. OSBORNE, Babak N. TOFIG
Filed: 10 Nov 22